Surgery alone remains an international standard of care for early stage (Ia) oesophagogastric cancers. There is also international consensus that multimodality therapy is appropriate for more advanced stage operable disease, however there is marked geographical variation in standard practice. For gastric adenocarcinomas, adjuvant oral fluoropyrimidines became the standard of care in Japan after improved survival was demonstrated following resection with D2 nodal dissection, compared to surgery alone. Adjuvant chemoradiation improves survival following surgery with any level of nodal dissection compared to observation and is the accepted standard of care in the US. Similarly, perioperative triplet chemotherapy improves survival compared to surgery alone in gastroesophageal adenocarcinomas and is widely used across Europe and Australasia. For oesophageal adenocarcinoma, neo-adjuvant chemotherapy and neo-adjuvant chemoradiation are further accepted standards, widely utilized in the UK and US respectively, with similar survival benefits reported for each strategy. Patients with localized squamous cell carcinomas of the oesophagus benefit from chemoradiation, which may be delivered as a neo-adjuvant or definitive strategy, the latter avoiding surgical morbidity and mortality. Targeted agents are currently under evaluation in localized oesophagogastric cancer, with translational sub-studies attempting to define which patients may benefit from the addition of these high cost drugs.
introduction
Despite a decline in the overall incidence [1], gastric cancer remains the second most common cause of cancer death worldwide [2] and thus a significant global health problem. A distinct geographical variation in incidence is well described, with the highest rates reported in East Asia, South America and Eastern Europe [1] , where non-cardia tumours predominate [2] . An increase in the proportion of gastric cancers arising at the gastric cardia/oesophagogastric junction (OGJ), most marked in the developed world [2] , may, at least in part, be attributed to rising levels of obesity and gastro-oesophageal reflux disease [3] . At present, the geographical variation in incidence is matched by a geographical variation in standard practice. In Japan, where a national screening programme enables diagnosis of early-stage disease, adjuvant oral fluoropyrimidine monotherapy following radical D2 resection results in unprecedented survival rates [4] . In the USA, patients will routinely be referred for adjuvant chemoradiation following resection, and, in Europe, combination chemotherapy delivered before and after D2 resection is the most widely accepted practice. Localized tumours of the OGJ and lower oesophagus are also frequently managed with the perioperative chemotherapy approach in Europe, whereas neoadjuvant chemoradiation is advocated in the USA.
Gastro-oesophageal cancer is most commonly diagnosed in male smokers between the ages of 60 and 80 years [1, 5] who will often have multiple co-morbidities, thereby increasing the challenge of delivering multimodality therapy.
The failure rate following current multimodality strategies remains unacceptably high, leading to the integration of targeted agents and translational research into current clinical trial design, with an urgent need for biomarkers predictive of benefit from chemotherapy and radiotherapy to allow treatment to be tailored to individual patients rather than the current 'one fits all' approach.
adjuvant chemotherapy
Despite the abundance of randomized studies of adjuvant chemotherapy for gastric cancer, only two trials conducted in the West have demonstrated a significant survival benefit over surgery alone. The first, a Spanish multicentre trial, randomized 148 patients with resected stage III gastric cancer to no further treatment or a combination of mitomycin C and oral tegafur for 3 months and reported an unexpectedly high 36% 5-year survival in those randomized to observation, which was increased to 52% with adjuvant chemotherapy [6] . Unfortunately, these data have not been consistently reproducible in a Western population, with only one further study reporting a significant survival benefit from an adjuvant regimen comprising epirubicin, 5-fluororuacil (5-FU) and leucovorin (LV) [7] , but six further studies using a variety of regimens showing no significant effect on survival from this strategy [8] [9] [10] [11] [12] [13] .
Following initial negative studies conducted in Japan, a significant survival benefit was demonstrated from adjuvant oral uracil-tagafur (UFT) delivered for 16 months following radical D2 resection in a study of 190 patients with serosa-negative, lymph node-positive (T2N1-2) gastric cancer. At a median follow up of 6.2 years, a hazard ratio (HR) for death of 0.48 [95% confidence interval (CI) 0.26-0.89, P = 0.017] in favour of chemotherapy was reported [14] . This was followed by a much larger study of the novel oral fluoropyrimidine S-1, a combination of tegafur and the enzyme inhibitors potassium oxonate and 5-chloro-2,4-dihydropyrimidine, the latter components included to improve gastrointestinal toxicity and efficacy, respectively. The ACTS-GC study randomized 1059 patients with stage II/III D2-resected gastric cancer to observation, or 1 year's treatment with S-1 monotherapy. The trial, which was stopped early due to positive efficacy results at interim analysis, demonstrated a significant improvement in 3-year survival from 70.1% with surgery alone to 80.1% with the addition of S-1 (HR 0.68, 95% CI 0.52-0.87, P = 0.002) [4] . The survival from surgery alone within the study is markedly longer than reported in any Western studies, probably due to a combination of the predominance of earlier stage disease and the high quality surgery mandated within the trial. Current adjuvant strategies under evaluation in clinical trials in Japan are compared with adjuvant S-1 as the new reference regimen. For example, the SAMIT trial has randomized 1480 patients in a 2·2 design to 11 months of adjuvant fluoropyrimidine monotherapy with UFT or S-1, or sequential paclitaxel for 3 months then UFT or S-1 for 8 months, and has recently completed accrual.
Whilst a 2002 meta-analysis of 21 adjuvant chemotherapy studies reported a significant overall benefit for chemotherapy (odds ratio 0.84, 95% CI 0.74-0.96) which was lost when the analysis was limited to Western groups (odds ratio 0.96, 95% CI 0.83-1.12) [15] , a more recent meta-analysis of 12 randomized studies, including the two positive Japanese trials, has shown an overall benefit from the strategy, with an HR for overall survival of 0.78 (95% CI 0.71-0.85) and no heterogeneity of effect by country of origin [16] . Whilst this confirms benefit from adjuvant chemotherapy, it is rarely used outside Japan without concomitant radiotherapy in the USA or neoadjuvant chemotherapy in Europe. Phase III studies which have changed clinical practice in localized gastric cancer are listed in Table 1 .
adjuvant chemoradiation
The Intergroup 0116 study established adjuvant 5-FU/LV chemoradiation, with radiotherapy delivered during the second of four cycles of adjuvant bolus 5-FU/LV chemotherapy, as the standard of care for gastric and OGJ cancer in the USA almost a decade ago [17] . Long-term follow-up data have confirmed an enduring survival benefit from the strategy, with an HR for survival of 1.32 (P = 0.004) reported at 10 years [18] . However, the role of radiotherapy in this setting has been questioned due to the associated toxicity, especially for patients who have undergone a radical D2 dissection. In the Intergroup study, D2 nodal dissection was recommended, but performed in only 10% of patients, with D1 resection performed in 36% of patients and D0 in the majority (54%). The authors reported no heterogeneity of treatment effect by the level of nodal dissection in a 2004 update [19] . However, this strategy has little popularity outside the USA, as radiotherapy is widely considered to be unnecessary after D2 dissection, unless a positive resection margin is detected at histopathological examination. The Korean ARTIST study, which completed accrual of 490 patients with resected stage Ib-IV gastric cancer in 2008, will determine the role of adjuvant radiation after D2 resection in a randomized comparison of adjuvant cisplatin and capecitabine with cisplatin/capecitabine chemoradiation.
perioperative chemotherapy
The UK Medical Research Adjuvant Gastric Infusional Chemotherapy (MAGIC) study changed clinical practice across Europe when a significant improvement in 5-year survival from three cycles of ECF (epirubicin, cisplatin, continuous infusion Annals of Oncology symposium article fluorouracil combination) chemotherapy delivered before and after surgery for patients with operable adenocarcinoma of the lower oeosphagus, OGJ or stomach was reported. Survival in the surgery alone arm was 23%, but increased to 36% with the addition of perioperative chemotherapy (HR 0.75, 95% CI 0.60-0.93, P = 0.009) [20] . Not all patients were able to undergo a curative resection; however, among patients that underwent radical surgery, the percentage of resections deemed curative by the surgeon was higher in the chemotherapy arm (79.3% compared with 70.3%, P = 0.03). Importantly, postoperative complication rates were similar in the two arms, including the postoperative mortality rate and duration of hospital stay. Surgery was scheduled 3-6 weeks after completion of cycle 3 of chemotherapy (median 99 days from randomization); therefore, this timing is usually adopted in clinical practice to minimize complications. Although 90% of patients that started chemotherapy completed the three neoadjuvant cycles, only 50% of patients that completed neoadjuvant therapy and surgery chemotherapy were also able to complete adjuvant chemotherapy. This illustrates the difficulty of delivering adjuvant strategies to this patient group following major surgery. The perioperative strategy is supported by a second study, presented in 2007, which remains unpublished at this time. The smaller Federation Nationale des Centres de Lutte Contre le Cancer (FNLCC) ACCORD07-FFCD 9703 trial randomized 224 patients with resectable adenocarcinoma of the stomach, OGJ or lower oesophagus to surgery alone or 2-3 cycles of cisplatin and 5-FU prior to resection. Postoperative chemotherapy was recommended for patients with a response to neoadjuvant therapy or stable disease as their best response but node-positive histology. Five-year overall survival was similar to that reported in the MAGIC study, at 24% with surgery alone and 38% in the chemotherapy arm (HR 0.69, 95% CI 0.50-0.95, P = 0.02) [21] . These data raise the question as to whether epirubicin is needed in the perioperative regimen. Of interest, 64% of patients in the FNLCC study had tumours involving the cardia, compared with 12% of patients in the MAGIC study, in which an apparently greater benefit was noted for this patient group on tests for heterogeneity (HR 0.44), although the difference was not statistically significant (P = 0.25) [20] . This difference in the patient population may explain the similar survival benefit reported in the French study, despite the use of a doublet rather than triplet regimen. The MAGIC regimen is now an accepted standard across Europe, and two current phase III studies will evaluate the addition of bevacizumab and adjuvant radiation to this regimen, respectively (Table 2 ). Of note, both studies have elected to use ECX, substituting capecitabine for infused 5-FU, extrapolating the non-inferiority for the oral fluoropyrimidine demonstrated in the advanced disease setting [22] .
neoadjuvant strategies
There are currently no phase III data to support a purely neoadjuvant strategy for operable gastric cancer. The EORTC 40954 study attempted to address the question of neoadjuvant chemotherapy for this patient group, using a combination of cisplatin, 5-FU and folinic acid (PLF) delivered for two cycles before surgery compared with surgery alone. However, the trial closed due to poor recruitment and although an increased rate A meta-analysis has reported a similar benefit for neoadjuvant chemotherapy or chemoradiation for oesophageal cancer, when the analysis is limited to patients with adenocarcinoma [24] . The Medical Research Council's OE02 study is the largest study included in the meta-analysis, in which 802 patients with resectable oesophageal cancer of any cell type were randomized to undergo two cycles of 3-weekly neoadjuvant cisplatin/5-FU chemotherapy or proceed directly to surgery [25] . Long-term follow-up has confirmed a modest but enduring survival benefit from neoadjuvant chemotherapy, with 5-year survival increased to 23% from 17.1% with surgery alone [26] . These results are in contrast to the earlier RTOG Trial 8911 (USA Intergroup 113) which had shown no survival benefit from three cycles of neoadjuvant cisplatin/5-FU using a 4-weekly regimen with higher doses of both agents [27] . Longterm follow-up of this study of 443 patients with localized oesophageal cancer confirmed no difference in survival by treatment arm in the intent to treat (ITT) population, but a significant survival benefit in patients that demonstrated an objective response to neoadjuvant chemotherapy on barium swallow examination [28] . The difference in outcome in the two studies may in part be due to the higher proportion of patients with squamous cell carcinomas (SCCs) in the RTOG study, who gain no significant benefit from chemotherapy on meta-analysis [24] , although no heterogeneity of effect by histopathological subtype was reported in either study [24] . In addition, the toxicity of the chemotherapy regimen utilized in the RTOG trial may be likely to have contributed to the negative result. The results of these studies are summarized in Table 3 .
Similarly, the results of studies of neoadjuvant chemoradiation for operable oesophageal cancer have been inconsistent. The first study which reported a benefit randomized 113 patients to undergo two cycles of cisplatin/5-FU, with 40 Gy of radiotherapy given concurrently with the first cycle, or surgery alone. The median survival was increased from 11 months with surgery alone to 16 months in those randomized to chemoradiation (P = 0.01) [29] . Despite the unexpectedly low survival with surgery alone and the small sample size, this study was the first to demonstrate a significant benefit from combined modality therapy, and changed clinical practice in the USA. An attempt to reproduce these data by the Trans-Tasman Radiation Oncology Group/Australasian Gastro-Intestinal Trials Group in a larger study of 256 randomized patients with resectable oesophageal cancer failed to demonstrate any significant benefit. This discrepancy may relate to the reduced exposure to chemotherapy in the Australasian study (only one cycle of cisplatin/5-FU was delivered) and/or the lower dose of radiation delivered (35 Gy). Of interest, a subgroup analysis demonstrated a significant survival benefit in the patients with SCC (P = 0.014) [30] . Most recently, despite poor accrual to the study, the CALGB 9781 study reported a significant improvement in overall survival in the 30 patients randomized to receive cisplatin/5-FU with radiotherapy of 50.4 Gy delivered during cycle 1 prior to resection, compared with the 26 patients randomized to surgery alone. Five-year overall survival was 39% in the trimodality arm compared with 16% in the standard arm, confirming the potential importance of this strategy [31] . However, the toxicity associated with chemoradiation is not unsubstantial, with a 30% rate of grade 3 infections and high rates of gastrointestinal toxicities in the CALGB study.
One further study of interest was published in 2009, comparing neoadjuvant chemotherapy with chemotherapy then chemoradiation in patients with T3/4 any N adenocarcinoma of the lower oesophagus or OGJ. Once again, the study was impeded by poor accrual but, in the 119 eligible patients analysed, a trend towards superiority of the trimodality regimen was reported, with 3-year survival increased from 27.7% to 47.4% (P = 0.07) with the addition of radiotherapy [32] . However, with the associated non-statistically significant increase in postoperative mortality from 3.8% to 10.2% (P = 0.26), whilst this strategy warrants further evaluation, patient selection for this approach is critical and further study essential to improve patient selection, possibly using novel imaging such as magnetic resonace imaging (MRI) to select patients at higher risk of a positive resection margin; a well-defined poor prognostic indicator [26] .
Novel neoadjuvant regimens are currently undergoing phase I/II evaluation, with refinement of chemotherapy regimens using taxanes, oxaliplatin or oral fluoropyrimidines in addition to the welcomed integration of targeted agents. These include the anti-epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab and panitumumab, the small molecule EGFR tyrosine kinase inhibitor gefitinib and the antivascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab. Selected current phase II studies integrating targeted agents into the treatment for resectable oesophageal cancer are listed in Table 4 .
chemoradiation for SCC of the oesophagus
Whilst patients with SCC were included in previous phase III studies of neoadjuvant chemotherapy [25, 27] , a meta-analysis has reported no significant benefit for chemotherapy compared with surgery alone (HR 0.88, 95% CI 0.75-1.03, P = 0.12). In contrast, the analysis confirmed a significant benefit from neoadjuvant chemoradiation in this patient group (HR 0.84, 95% CI 0.71-0.99, P = 0.04) [24] . Results from clinical trials of neoadjuvant chemoradiation conducted in SCC alone have been inconsistent, most probably due to variations in the total radiotherapy dose delivered, sequential or concurrent administration of the two modalities and the chemotherapy regimen chosen; each with resulting effects on toxicity and efficacy [33] [34] [35] [36] [37] . These trials, none of which individually demonstrated a statistically significant survival advantage, are summarized in Table 5 .
Due to the significant mortality and morbidity associated with surgery and the co-morbidities that patients with SCC may present with, two phase III studies have evaluated the avoidance of surgery altogether, using definitive chemoradiation. The first study to demonstrate the feasibility symposium article Annals of Oncology of this strategy randomized 172 patients to undergo induction chemotherapy with bolus 5-FU/LV, cisplatin and etoposide then chemoradiation (40 Gy) followed by surgery, or the same induction chemotherapy followed by chemoradiation (at least 65 Gy) without surgery. Overall survival was equivalent in the two groups, with a 2-year survival of 39.9% and 35.4% 
Annals of Oncology symposium article
(log-rank test for equivalence, P = 0.007) for the surgery and non-surgery arms, respectively. However, 2-year local progression-free survival was superior in the surgery group (64.3% compared with 40.7%; HR 2.1, 95% CI 1.3-3.5, P = 0.003), balanced by significantly more treatment-related mortality (12.8% compared with 3.5% without surgery, P = 0.03). Response to induction chemotherapy was an independent prognostic factor for overall survival [38] . More recently, the results of a French study comparing definitive 5-FU/cisplatin-based chemoradiation with chemoradiation then surgery in responders to induction chemoradiation reported non-inferiority of the non-surgical approach in the 259 patients randomized. The 2-year survival rate was 34% with surgery compared with 40% with definitive chemoradiation (HR 0.90, P = 0.44) [39] . The study, which was complicated by an additional comparison of conventional and split-course radiation, could also be criticized for not randomizing all registered patients. However, the results are possibly more relevant to clinical practice for this decision not to randomize or analyse the overall population, as there can be no value to continuing to treat non-responding patients with therapy to which they have demonstrated resistance. To build upon these data, the Wales Cancer Trials Unit SCOPE study will evaluate the addition of the anti-EGFR monoclonal antibody cetuximab to definitive chemoradiation with cisplatin and capecitabine for localized oesophageal cancer unsuitable for surgery.
future clinical trial designs
It is essential that current studies include tissue collection for biomarker evaluation within their design, so that future studies can select patients most likely to benefit from these agents. A notable example of the successful addition of a targeted agent to gastro-oesophageal cancer treatment is the randomized phase III ToGA study, which selected patients by HER2 overexpression measured by immunohistochemistry (IHC) and FISH, and reported a statistically significant improvement in response rate, progression-free and overall survival with the addition of trastuzumab to cisplatin plus fluoropyrimidine chemotherapy for patients with advanced disease. In an exploratory analysis, patients with the highest level of expression (IHC 2+ or 3+ and FISH+) gained a greater survival advantage, which clearly demonstrates the importance of careful biomarker selection for studies [40] . In contrast, a multicentre phase II study of a small molecule dual MET and VEGFR2 inhibitor was evaluated in an unselected population in advanced gastro-oesophageal cancer. C-met amplification was reported in just 7% of the 43 evaluable patients and minimal activity was observed in the overall cohort [41] . The development of novel agents must be paralleled by translational research into potential biomarkers for these therapies. Molecular predictors of efficacy and prognosis will prevent potentially valuable novel agents being discarded inappropriately during early phase testing. 2-[ 18 F]Fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET) appears to be a useful metabolic predictor of response to neoadjuvant therapy in gastrooesophageal cancer and is a strong prognostic indicator [42] . The phase II MUNICON study was designed to use metabolic response assessed by FDG-PET to guide treatment after an initial cycle of cisplatin/fluoropyrimidine-based neoadjuvant chemotherapy. Patients with a metabolic response continued neoadjuvant chemotherapy for a total of 12 weeks, whereas metabolic non-responders proceeded straight to surgery. Significantly longer median event-free and overall survivals were reported in the metabolic responders, confirming the use of this strategy for responding patients [43] . However, the survival in non-responders was poor, and novel strategies needed to be evaluated for this group. An example of such a study (NCT00737438) underway in the USA in patients with operable gastric and OGJ adenocarcinoma builds on the results of the MUNICON study [43] . Rather than metabolic non-responders proceeding to surgery with the poor survival this confers, this study utilizes a novel salvage regimen comprising bevacizumab, docetaxel and irinotecan for metabolic non-responders after one cycle of ECX plus bevacizumab. Patients with a good metabolic response will complete a further two cycles of ECX plus bevacizumab before proceeding to resection.
MRI may also have a role as a staging tool in future clinical trial design. In phase III studies in oesophageal and OGJ tumours, the percentage of positive resection margins (R1) has been unacceptably high: in the long-term follow-up reports from the OE02 and RTOG 8911 studies, the percentage of R0 complete resections were just 57% [26] and 61% [28] , respectively. Whilst staging techniques have improved since these studies were conducted and contemporary staging will usually include endoscopic ultrasound and PET scans, improved assessment of circumferential resection margins may still be gained with the inclusion of MRI; although data are currently limited.
conclusions
Despite increasing focus on a personalized approach to medicine, multimodality therapy for localized gastro-oesophageal cancer remains largely determined by tumour site, histological subtype, patient co-morbidities and performance status. In current clinical practice, there is little emphasis on molecular characteristics within the treatment paradigm. It is these authors' hope that the results of present and future clinical trials will move clinical practice away from these standardized approaches and towards a personalized treatment approach based upon the molecular profile of an individual patient's disease. acknowledgement
